XEROSTOMIA THERAPEUTICS MARKET ANALYSIS

Leading Companies

Global Xerostomia Therapeutics Market: Competitive landscape

The major players operating in the xerostomia therapeutics market include Eisai Inc., Hikma Pharmaceuticals, Synedgen, 3M, Lupin Pharmaceuticals, Inc., Apotex Inc., Church & Dwight Co. Inc., Parnell Pharmaceuticals, Colgate-Palmolive Co., EUSA Pharma, Cumberland Pharmaceuticals Inc., OraHealth Inc., Daiichi Sankyo Co. Ltd., Forward Science, Eisai Co. Ltd., GlaxoSmithKline Plc, Pharmascience Inc., Mission Pharmacal Company, Quest Products Inc., Saliwell Ltd., Sun Pharmaceutical Industries Ltd., and Dentaid.

Market players are focused on adoption of inorganic growth strategies such as acquisitions and collaborations, in order to enhance their product portfolio in the potential market. For instance, in July 2015, Hikma Pharmaceuticals acquired Roxane Laboratories, which is a part of West-Ward Pharmaceuticals Corp, for product profile enhancement in oral care segment. Moreover, in May 2018, Moisyn products developed by the oral care division of Synedgen have been approved for marketing by the U.S. Food and Drug Administration (FDA) to treat xerostomia.